aldehyde/1 % agarose gel (25) , and transferred to nylon membranes by capillary blotting (Amersham Corp., Arlington Heights, IL) (26) . The membranes were exposed to short-wave UV light for 30 s to fix the RNA to the nylon matrix, and treated at 42°C for 4 h with prehybridization solution containing 10% dextran before incubation with 12 P-labeled nucleic acid probe. The probes used were IL-4 cDNA subcloned into pSP65 (2) , and the 550-bp Eco RI/Eco RV fragment of murine IFN-y (Dr. P W. Gray, Genentech, Inc .) subcloned into PSP72 (Promega Biotec, Madison, WI) . IFN-y and IL-4 antisense probes were generated using 12P-CTP (800 Ci/mmole ; New England Nuclear, Boston, MA) and SP6 RNA polymerase (Promega Biotec) as described (2) . Membranes were hybridized with antisense RNA probes at 65°C overnight, and washed in 0 .1% SDS, 0 .1 x SSC (0 .015 M NaCl, 0 .0015 M sodium citrate buffer, pH 7 .0) at 65°C. Membranes were hybridized with nick-translated cDNA probe at 42°C overnight and washed in 0 .1% SDS, 0 .1 x SSC at 55°C. Washed membranes were exposed to X-ray film as previously described (2) .
Serum IgE Determinations.
Sera isolated before death were quantitated for IgE using a sandwich ELISA with monoclonal anti-e (EM-95) as the primary antibody and biotinylated polyclonal rabbit-anti-4E as the secondary antibody, as described (27) .
Results
Effect of Exogenous rIFN-y in Infected BALBIc Mice. The low levels of IFN-'y produced during progressive L. major infection in susceptible BALB/c mice, in contrast to the readily detectable levels produced by resistant C57BL/6 mice (1, 2), suggested that parenterally administered rIFN-y might favorably influence the outcome of infection in the BALB/c mice. Based on preliminary experiments, a dose of IFN-y that was twofold below that resulting in toxicity to infected mice was used. This dose, 20 ug every 48 h, was twice that used to cure otherwise fatal murine Toxoplasma gondii (28, 29) or Trypanosoma cruzi (30) infection . Infected BALB/c mice receiving rIFN-y demonstrated a slight delay in footpad swelling (Fig. 1) , but ulceration and histologic evidence of extensive parasitization occurred in all animals (Fig. 2 C) . At 5 wk post-infection, however, treated mice had significant diminution in serum IgE levels compared with control-infected mice (Fig . 3) , indicating in vivo efficacy of the exogenous IFN-'Y (27) Effect of rIFN-y or anti-IL-4 treatment on the progression ofL. major infection in BALB/c mice . Footpad measurements represent the mean t SEM from 48 mice after no treatment (O) or anti-IL-4 treatment ( "), and the mean t SEM from five mice after rIFN-y treatment (A) . significant attenuation of disease as compared with matched untreated animals ( Fig .  1) . Footpad swelling was markedly decreased and began to resolve after 6 wk, whereas footpads of the control animals progressed to ulceration and necrosis . Although disease did progress, albeit more slowly, in some of the treated mice, 85% were com- In contrast, BALB/c mice that received weekly injections of either nonimmune rat sera or isotype-matched R4 6A2 anti-IFN--y (rat IgGI) developed disease and elevated serum IgE levels indistinguishable from those in untreated infected BALB/c mice (data not shown) .
Anti-IL-4 Effect Is Dependent on T Cells.
When healed, anti-IL-4-treated BALB/c mice were rechallenged with viable promastigotes, they remained immune to reinfection (data not shown) . Pooled spleen and lymph node cells from anti-IL-4-treated BALB/c mice that had resolved the primary infection were transferred into irradiated BALB/c recipients before challenge with L. major promastigotes. These mice, but not mice receiving naive BALB/c spleen cells, displayed substantial protection against the parasite, as assessed both by footpad swelling and ulceration (Fig . 4) . 6 wk is indicated. Prior irradiation at these doses (in contrast to higher doses [9] ) had no effect on the subsequent course of leishmaniasis as compared with nonirradiated controls . Treatment of the pooled cells with either anti-CD4 or anti-CD8 plus complement significantly abrogated the capacity of the transferred cells to prevent footpad swelling and completely reversed the prevention of ulceration . To establish further the requirement for T cells in the efficacy of anti-IL-4, athymic BALB/c nu/nu mice, which are unable to control leishmaniasis in the absence of T cell reconstitution (31), were infected with L. major. Such mice showed no alteration of disease progression in response to weekly anti-IL-4 injections (Fig. 5) . Although footpad swelling was delayed in nude mice as compared with normal infected BALB/c mice, as previously reported (31), histologic analysis of the infected footpads and lymph nodes at week 6 revealed extensive parasitization of macrophages from both control and anti-IL-4-treated nude mice (data not shown) . Effect ofAnti-IL-4 on IFN-y and IL-4 mRNA . Prior studies have documented the correlation between the presence of IFN-y mRNA and the capacity to heal L. major infection (1, 2) . To assess the possible role of IFN-y in the therapeutic response of anti-IL-4-treated mice, mRNA extracted from the spleens and lymph nodes of infected mice was examined for IFN-y-specific transcripts . Although Northern blot analysis of splenic IFN-y mRNA from the anti-IL-4-healed BALB/c mice revealed no differences as compared with untreated mice (Fig . 6, lanes A and B) , message levels in the draining lymph nodes were approximately fourfold enhanced (Fig . 6,  lanes C and D) . Analysis of IL-4 mRNA in the same tissues similarly revealed no change in splenic message levels accompanying anti-IL-4 treatment, but a reciprocal fourfold decrease in specific mRNA in lymph node mRNA.
IFN-y Does not Mediate Healing Induced by Anti-IL-4. To investigate further the mechanism of healing, in vivo neutralization of IFN-y with anti-IFN-y mAb, R4 6A2, was used to assess the role of this cytokine in anti-IL-4-treated BALB/c, C57BL/6, and GK1.5-BALB/c mice .
L. major-infected BALB/c mice receiving both anti-IL-4 and anti-IFN-1' antibodies contained the infection, as well as those receiving anti-IL-4 alone (Fig. 7 A) . In marked contrast, infected C57BL/6 mice receiving anti-IFN-y demonstrated progressive swelling of the footpads with ulceration by week 5 (Fig . 7 B) footpad swelling and the presence of numerous parasites was confirmed by histologic examination of the footpads in which amastigote-parasitized macrophages were readily detectable (Fig . 8 B) . Untreated C57BL/6 mice responded to infection with footpad swelling through the first 5-6 wk, followed by resolution without ulceration (Fig . 7 B) . Resolution of disease was confirmed by histologic examination (Fig. 8 A) . Similar results were seen when GK1.5-BALB/c mice were treated with anti-IFN--y . Neutralization of IFN-y resulted in progressive infection as assessed both by size of the local lesions and increasing numbers of amastigote-infected macrophages in the footpads (Figs. 7 C and 8, C and D, respectively). In both C57BL/6 and GK1.5-BALB/c mice, neutralization of IFN-y resulted in significant increases in serum IgE levels as compared with untreated infected mice (Fig . 3) .
Discussion
These studies demonstrate the profound effect of neutralization of IL-4 on the course of otherwise fatal infection by L. major in susceptible BALB/c mice . All treated mice had attenuated disease, and 85% were cured. The efficacy of anti-IL-4 treatment required the presence of T cells, and anti-IL-4-induced protection could be adoptively transferred in a manner dependent on both CD4+ and CD8 + cells. Surprisingly, there was no evidence that cure was mediated by the generation of IFN-'r, despite the demonstration that this cytokine was critical for healing in C57BL/6 or GK1.5-BALB/c mice. Further, treatment with rIFN-y alone was insufficient to affect the course of disease in infected BALB/c mice, a finding consistent with at least two mechanisms for establishing control of leishmaniasis. The effect of anti-IL-4 therapy was established by measurement of footpad thickness, histologic examinations demonstrating absence of parasites, and resistance of mice to rechallenge with promastigotes 12 wk subsequent to the initial infection . Neither control rat sera nor an isotype-matched mAb had any effect on the course of disease, suggesting that neutralization of IL-4 is required for activity. The finding that anti-IL-4 therapy abrogated the rise in serum IgE seen in untreated, infected BALB/c mice further documents the neutralization of IL-4 in vivo (32) (33) (34) . Treatment of infected nu/nu BALB/c mice with anti-IL-4 had no effect on the course of disease, indicating that T cells are required . The latter experiment further excluded the possibility of direct antileishmanial activity by the anti-IL-4 mAb.
Because IL-4 has been proposed as a requisite growth factor for Th2 cells (13, 35) , our initial assumption was that anti-IL-4 therapy was effective due to a selective blockade of the expansion of Leishmania antigen-specific Th2 cells. The decrease in IL-4 mRNA and reciprocal increase in IFN-y mRNA that occurred in the lymph node cells draining the lesion were consistent with a proportionately greater expansion of Thl cells in response to inhibition of Th2 cell division by anti-IL-4. However, several observations suggest that this may not be the only mechanism. rIFN-y has also been shown to effectively block Th2 cell proliferation in vitro (36) , but despite administration of rIFN-y at doses shown to effectively ameliorate fatal infection by T. gondii (29, 30) (2) with resolution of infection. The identification of IFN-y as a major macrophageactivating factor and the requirement for macrophage activation to kill this intracellular parasite have been well established (5, 7, 30, 39) . The studies reported here demonstrate that IFN-y is required for healing in these mice, since the administration of neutralizing anti-IFN-y antibody resulted in progressive, uncontrolled infection both in C57BL/6-and anti-CD4-pretreated BALB/c mice. Similar findings have been reported recently in studies of L. major infection in C3H/HeN mice (40) . Despite the requirement for IFN-y in resolution of disease in these mice, rIFN-y did not protect BALB/c mice by itself. It did not enhance the therapeutic effects of anti-IL-4 either, suggesting that while important to the outcome of disease, IFN-y is not sufficient by itself for the resolution of leishmaniasis in BALB/c mice.
Importantly, cure mediated by neutralization of IL-4 appeared independent of IFN-y, since cotreatment of these mice with neutralizing anti-IFN-y mAb did not abrogate the therapeutic effect of the anti-IL-4. Treatment with anti-IL-4 established protective cellular immunity, as assessed by cell transfer experiments, that resided in both the CD4+ and CD8+ populations. Although CD4 depletion was slightly more effective than CD8 depletion in reversing the attenuation of footpad swelling, the CD8 requirement supports recent observations establishing a protective role for these cells in leishmaniasis (41, 42) . The possibility that macrophage-activating factors other than IFN-y (43, 44) or contact-mediated macrophage activation (45, 46) are involved in the mechanism underlying the potent effects of anti-IL-4 therapy of leishmaniasis remains to be established . The elucidation of the mechanisms involved should uncover novel redundant systems for the control of intracellular pathogens.
Summary
BALB/c mice infected with Leishmania major develop fatal, progressive disease, despite an immune response characterized by expansion of CD4+ T cells in the draining lymph nodes. The immune response has been further characterized by a lack of IFN-y mRNA, but increased IL-4 mRNA in lymphoid tissues, and striking elevation of serum IgE. Treatment of infected BALB/c mice with rIFN-y at doses shown to be beneficial in other protozoan infections was insufficient to ameliorate L. major infection. In contrast, neutralization of IL-4 by six weekly injections of mAb 111311 led to attenuation of disease in 100% of animals, and complete cure in 85%. Resolution of disease required the presence of T cells, and recovered mice remained resistant to reinfection at 12 wk . This immunity was adoptively transferable and was dependent on both CD4' and CD8+ cells. Although administration of anti-IL-4 was associated with fourfold increase in IFN-y mRNA in lymph node cells draining the lesion, the coadministration of neutralizing R4 6A2 anti-IFN-y mAb had no effect on resistance to disease. This was in marked contrast to resolution of disease in both resistant C57BL/6-and GK1.5-pretreated BALB/c mice that was abrogated by in vivo treatment with anti-IFN-y . These data suggest a novel mechanism of cel-
